AIM Immunologicals Group

AIM ImmunoTech is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases. The company's flagship product is Ampligen (rintatolimod), a double-stranded RNA (dsRNA) molecule that acts as a Toll-like receptor 3 (TLR3) agonist to modulate the immune system. AIM ImmunoTech is currently evaluating Ampligen in various clinical trials for indications including pancreatic cancer, ovarian cancer, breast cancer, and Long COVID. While Ampligen has received approval for Chronic Fatigue Syndrome in Argentina, the company continues to pursue regulatory pathways in the United States and other global markets.